Form 8-K - Current report:
SEC Accession No. 0001104659-25-061397
Filing Date
2025-06-23
Accepted
2025-06-23 07:41:43
Documents
18
Period of Report
2025-06-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518620d1_8k.htm   iXBRL 8-K 70930
2 EXHIBIT 2.1 tm2518620d1_ex2-1.htm EX-2.1 702661
3 EXHIBIT 10.1 tm2518620d1_ex10-1.htm EX-10.1 144006
4 EXHIBIT 10.2 tm2518620d1_ex10-2.htm EX-10.2 100925
5 EXHIBIT 10.3 tm2518620d1_ex10-3.htm EX-10.3 102501
6 EXHIBIT 10.4 tm2518620d1_ex10-4.htm EX-10.4 27493
7 EXHIBIT 99.1 tm2518620d1_ex99-1.htm EX-99.1 32318
  Complete submission text file 0001104659-25-061397.txt   1611080

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA carm-20250622.xsd EX-101.SCH 3017
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20250622_lab.xml EX-101.LAB 34239
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20250622_pre.xml EX-101.PRE 22360
20 EXTRACTED XBRL INSTANCE DOCUMENT tm2518620d1_8k_htm.xml XML 3697
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 251062974
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)